FTC Chair: Orange Book Scrutiny Will Increase Despite Inhaler Price Caps

Federal Trade Commission (FTC) Chair Lina Khan says capping inhaler prices and not delisting patents from the Orange Book are two separate issues and the commission will continue to scrutinize patents wrongfully listed in the Orange Book despite the industry’s moves to lower inhaler prices and plan to disclose additional information in the coming weeks. Meanwhile, the Supreme Court refused to consider a court case over whether drug patents can be invalidated on the basis that the inventions are “obvious.”...